1 PharmD Intern Nazareth College of Pharmacy, Othera, Thiruvalla, Kerala, India.
2 Assistant Professor Department of Pharmacology, Believers Church Medical College Hospital, Thiruvalla, Kerala, India.
3 Clinical Pharmacist, Believers Church Medical College Hospital, Thiruvalla.
4 Tutor Department of Pharmacology, Believers Church Medical College Hospital, Thiruvalla, Kerala, India.
5 Professor Department of Pharmacology, Believers Church Medical College Hospital, Thiruvalla, Kerala, India.
World Journal of Biology Pharmacy and Health Sciences, 2025, 23(01), 323–328
Article DOI: 10.30574/wjbphs.2025.23.1.0679
Received on 06 June 2025; revised on 13 July 2025; accepted on 15 July 2025
Mefenamic acid is a non-selective non-steroidal anti-inflammatory drug (NSAIDs) used in the management of pain and inflammation. They are non-opioid analgesics. They inhibit the synthesis of prostaglandins in body tissues by inhibiting COX-1 and COX-2. Thus inhibits the synthesis of prostaglandins, reducing blood supply to the kidneys. Hence, there is always a possibility of kidney injury after administration of Mefenamic acid. We hereby present a series of 7 patients where they developed kidney injury while on treatment with Mefenamic acid.
Mefenamic Acid; NSAID; Pain and Inflammation; CKD; Acute Kidney Injury; DIKI
Preview Article PDF
Sharon Wilson, Sara Kurien Kodiattu, Harikrishnan S, Kavya Annie Rojin and R S Jacob Jesurun. Mefenamic acid and renal health: Unveiling the risks. World Journal of Biology Pharmacy and Health Sciences, 2025, 23(01), 323-328. Article DOI: https://doi.org/10.30574/wjbphs.2025.23.1.0679.